๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanchang
Clinical trial register · China

Clinical Trials in Nanchang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Nanchang University32 AbbVie15 The First Affiliated Hospital of Nanchang University14 Sun Yat-sen University12 Jiangxi Provincial Cancer Hospital12
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanchang

432 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Fulvestrant
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Pomalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
DrugsAbiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms
NCT04289480Intracranial Aneurysm
Medos International SARL
Observational
164
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang, Shanghai
2020-07-30
Recruiting
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
NCT04481763Triple-Negative Breast Cancer
DrugCamrelizumab
Jiangxi Provincial Cancer Hospital
Phase 1/2
20
Nanchang
2020-07-14
Active, closed
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358Cholestasis
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
NCT04275518Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.
Phase 1
102
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Nanchang, Changchun
2020-07-06
Recruiting
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
NCT04425265Surgery, Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Not applicable
500
Guangzhou, Zhuhai, Nanchang
2020-06-30
Active, closed
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409Plasma Cell Myeloma
DrugsIsatuximab SAR650984·Montelukast·Equivalent)·Diphenhydramine
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
Active, closed
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
NCT04397211Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542Prostate Cancer
DrugsXaluritamig·Abiraterone·Enzalutamide
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
NCT03907826Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2020-03-01
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
DrugsTucatinib·Trastuzumab emtansine
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Active, closed
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04076059Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Recruiting
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
NCT04135664Esophageal Cancer
Shanghai Chest Hospital
Phase 3
176
Nanchang, Shanghai, Tianjin
2019-09-01
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
DrugsAcalabrutinib·Obinutuzumab·Venetoclax
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Recruiting
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC๏ผ‰
NCT03941561Gastric Cancer
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Recruiting
Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH
NCT05738083Aneurysmal Subarachnoid Hemorrhage
Second Affiliated Hospital of Nanchang University
Observational
5,000
Nanchang
2018-10-01
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
1,336
Guangzhou, Shijiazhuang, Wuhan, Changsha, Nanchang, Shanghai, Chengdu, Tianjin
2018-04-09
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Pembrolizumab·Paclitaxel
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
DrugsCobimetinib·Vemurafenib·Divarasib·Entrectinib
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
NCT03255694Dwarfism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
DrugUpadacitinib
AbbVie
Phase 3
950
Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai
2017-01-31
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Beijing, Chongqing, Jiamusi, Jiโ€™an, Kaifeng, Liaocheng, Lishui, Nanchang
2016-12
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
DrugsBicalutamide·Apalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Recruiting
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
NCT07595094Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction, Disease Risk Prediction
Second Affiliated Hospital of Nanchang University
Observational
2,000,000
Nanchang
2006-06-01
Recruiting
Clinical Risk Score Prediction for Risk of Dementia Among Late-life Population With Depression
NCT07676851Alzheimer Dementia (AD), Dementia, Late Life Depression (LLD), Risk Scores
Second Affiliated Hospital of Nanchang University
Observational
44
Nanchang
2006-06-01
Rows per page Showing 401–432 of 432
Previous 3 4 5
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanchang?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 432 of those studies with a site in Nanchang.

How many clinical trials are recruiting in Nanchang?

272 of the 432 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 57 have not yet opened recruitment, 94 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.